11/01/2022
The indication for Laser Therapy have become so wide since Laser was first FDA Cleared in the U.S. in October 2002. Happy 20th birthday in the U.S. to Laser Therapy.
If you are not yet utilizing Laser Therapy in your practice, what are you waiting for?
Reach out to Harlan Health Products, Inc. We will equip you with the right equipment, get you trained, and provide 5 Star support forever!!!
www.HarlanHealth.com 1-800-345-1124
๐๐๐๐ข๐๐๐๐ฒ ๐จ๐ ๐ฅ๐จ๐ฐ-๐ฅ๐๐ฏ๐๐ฅ ๐ฅ๐๐ฌ๐๐ซ ๐ญ๐ก๐๐ซ๐๐ฉ๐ฒ ๐ข๐ง ๐ญ๐๐ฆ๐ฉ๐จ๐ซ๐จ๐ฆ๐๐ง๐๐ข๐๐ฎ๐ฅ๐๐ซ ๐๐ข๐ฌ๐จ๐ซ๐๐๐ซ๐ฌ: ๐ ๐ฌ๐ฒ๐ฌ๐ญ๐๐ฆ๐๐ญ๐ข๐ ๐ซ๐๐ฏ๐ข๐๐ฐ
Deepankar Shukla and M. R. Muthusekhar
Low-level laser therapy (LLLT) has been commonly used for the treatment of painful musculoskeletal conditions, but the results of previous studies on this subject are controversial. The aim of this study was to evaluate the efficacy of LLLT in the management of patients with myogenic temporomandibular joint disorders (TMDs). In this randomized, double-blind clinical trial, 20 patients with myogenic TMD were randomly divided into laser and placebo groups. In the laser group, a pulsed 810-nm low-level laser (average power 50 mW, peak power 80 W, 1,500 Hz, 120 s, 6 J, and 3.4 J/cm2 per point) was used on painful muscles three times a week for 4 weeks. In the placebo group, the treatment was the same as that in the laser group, but without energy output. The patients were evaluated before laser therapy (T1), after six sessions of laser application (T2), at the end of treatment (T3), and 1 month after the last application (T4), and the level of pain and the amount of mouth opening were measured. There was a significant increase in mouth opening and a significant reduction of pain symptoms in the laser group (p < 0.05). A similar improvement was not observed in the placebo group (p > 0.05). Between-group comparisons revealed no significant difference in pain intensity and mouth opening measurement at any of the evaluation time points (p > 0.05). LLLT can produce a significant improvement in pain level and mouth opening in patients affected with myogenic TMD.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242077/